Mastering Diagnostic Patterns for Inborn Errors of Immunity in Pediatric Practice

A structured expert-elicitation study distributed through JoVE Visualize and Pediatric Allergy and Immunology has done something the field quietly needed: it compiled diagnostic red flags and pitfalls for inborn errors of immunity into a usable pattern-recognition framework. In my experience running pediatric cohorts, that distinction matters more than any new genetic panel. Recognition still drives the workup.

The framework flags disseminated BCG or other mycobacterial disease, very-early-onset inflammatory bowel disease, and infant lymphopenia as priority triggers. It also delivers a sober reminder that a normal mean platelet volume does not exclude Wiskott–Aldrich syndrome. That last point alone should keep front-line clinicians from anchoring on a single CBC parameter. The pattern is the diagnosis; the lab is the confirmation.

Adjacent signals worth tracking

The same week brought two diagnostic confirmations and one regulatory nudge that frame where pediatric immunology is heading. The Times of India reported an AIIMS study tying late diagnosis of rare kidney disease to stunted growth in children — a reminder that diagnostic delay in immune-mediated or syndromic disease is rarely a neutral event. Cureus published a case report of Noonan Syndrome Type 5 diagnosed by next-generation sequencing, underscoring that targeted panels and exome approaches are now routinely closing gaps where phenotype-first workups stall.

On the therapeutic side, BioSpace carried word that Mahzi Therapeutics received FDA Rare Pediatric Disease Designation for MZ-1866, an investigational therapy for Pitt Hopkins Syndrome. Designation is not approval and does not validate an efficacy endpoint, but it does mark another syndromic neurodevelopmental disorder entering the regulatory pipeline — a useful data point for clinicians tracking how orphan gene-disorder programs are maturing.

What I am actually watching

Pearls-and-pitfalls papers tend to age quickly when the next consensus meeting revises them, so I treat frameworks like this as scaffolding, not gospel. What I want to see next: validation cohorts that test whether following these red flags shortens time-to-diagnosis in real-world pediatric immunology clinics, and whether the pitfalls list reduces misattribution — particularly the WAS misread on a normal MPV. The diagnostic odyssey is measured in years for many families; pattern recognition is the cheapest intervention we have. Until those cohorts report, I file this framework on the desk, not in the protocol.